Xhance™ (fluticasone propionate / previously known as OPN-375), a synthetic trifluorinated corticosteroid, is...
Bellus Health starts recruitment in Phase II chronic cough trial
Canadian biopharmaceutical firm Bellus Health has commenced patient enrolment in the Phase II RELIEF clinical trial of BLU-5937 to treat refractory chronic cough.
Frequency’s FX-322 improves hearing function in trial subjects
Biotechnology company Frequency Therapeutics has reported positive data from a Phase I/II clinical trial of investigational drug FX-322 intended for hearing restoration.
Xhance™ (fluticasone propionate) for the Treatment of Nasal Polyps
Xhance™ (fluticasone propionate / previously known as OPN-375), a synthetic trifluorinated corticosteroid, is indicated for the treatment of nasal polyps in patients aged 18 years or older.